自激活激酶ULK1mRNA的α-Globin降低和增加来自治疗sirolimus的β-thalassemia患者的红色素前体中的α-Globin降低和增加
Matteo Zurlo1, Cristina Zuccato1,2, Lucia Carmela Cosenza1
1Department of Life Sciences and Biotechnology, Ferrara University, 44121 Ferrara, Italy.
International journal of molecular sciences
|October 28, 2023
概括
治疗β-thalassemia的sirolimus可能会通过增加自和ULK-1表达来减少有害的α-格洛宾. 这表明西洛是这些遗传性血液疾病的有前途的治疗策略.
科学领域:
- 血液学 血液学 血液学
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- β-thalassemia是一种遗传性疾病,导致成人血红蛋白降低和毒性过多的α-globin,导致无效的红色素形成.
- 减少多余的α-环球蛋白是关键的治疗目标,可以通过胎儿血红蛋白诱导或自来实现.
- 西洛利斯 (拉帕米辛) 和其类似物显示出诱导胎儿血红蛋白 (HbF) 在血红蛋白病的潜力.
研究的目的:
- 为了研究西洛斯对自的作用,ULK-1表达和红色素前体的α-环球蛋白降低.
- 在一项临床试验中,评估西洛利木斯对白色素前体的这些标记物的影响,从β-thalassemia患者.
主要方法:
- 用低剂量西洛素进行红色素前体 (ErPC) 的体外刺激.
- 对自标志物 (p62),ULK-1表达 (蛋白质和mRNA) 和α-环球蛋白含量的分析.
- 在NCT03877809临床试验中治疗的β-thalassemia患者的ErPCs的分离和分析.
主要成果:
- 低剂量西洛斯在体外降低了p62,增加了ULK-1表达,并减少了ErPC中的过量α-环球蛋白.
- 接受西洛斯治疗的患者的ErPC显示ULK-1mRNA增加和α-globin减少.
- 这些发现表明,西洛斯会影响与β-thalassemia相关的关键通路.
结论:
- 赛洛斯治疗与β-thalassemia中过量的α-globin减少有关.
- 自和ULK-1表达是西洛斯疗效的潜在生物标志物.
- 这些细胞机制和标记物应在针对β-thalassemia的 sirolimus 基临床试验中考虑.
相关概念视频
iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
Erythropoiesis
4.3K
Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
4.3K
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K


